Dimensional Fund Advisors LP Grows Stock Holdings in Amedisys, Inc. (NASDAQ:AMED)

Dimensional Fund Advisors LP increased its position in shares of Amedisys, Inc. (NASDAQ:AMED) by 4.0% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 514,166 shares of the health services provider’s stock after buying an additional 19,660 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Amedisys were worth $47,202,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Banque Cantonale Vaudoise purchased a new stake in Amedisys during the first quarter worth $60,000. Innealta Capital LLC purchased a new stake in Amedisys during the second quarter worth $64,000. Covestor Ltd boosted its holdings in Amedisys by 134.2% during the first quarter. Covestor Ltd now owns 780 shares of the health services provider’s stock worth $72,000 after buying an additional 447 shares in the last quarter. Signaturefd LLC boosted its holdings in Amedisys by 88.2% during the second quarter. Signaturefd LLC now owns 1,131 shares of the health services provider’s stock worth $104,000 after buying an additional 530 shares in the last quarter. Finally, GAM Holding AG purchased a new stake in Amedisys during the second quarter worth $275,000. 94.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have weighed in on AMED. Deutsche Bank Aktiengesellschaft cut shares of Amedisys from a “buy” rating to a “hold” rating and set a $101.00 price objective for the company. in a research report on Monday, July 29th. Cantor Fitzgerald restated a “neutral” rating and set a $101.00 price objective on shares of Amedisys in a research report on Thursday, July 25th. Finally, William Blair cut shares of Amedisys from an “outperform” rating to a “market perform” rating in a research report on Monday, July 1st. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $100.67.

Amedisys Price Performance

Shares of NASDAQ AMED opened at $96.63 on Monday. The firm has a 50-day simple moving average of $97.61 and a 200-day simple moving average of $94.98. The stock has a market capitalization of $3.16 billion, a price-to-earnings ratio of -150.98, a price-to-earnings-growth ratio of 1.90 and a beta of 0.78. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 0.30. Amedisys, Inc. has a 52 week low of $89.55 and a 52 week high of $98.95.

Amedisys (NASDAQ:AMED) last issued its earnings results on Wednesday, July 24th. The health services provider reported $1.32 EPS for the quarter, beating analysts’ consensus estimates of $1.22 by $0.10. Amedisys had a net margin of 4.02% and a return on equity of 12.39%. The business had revenue of $591.19 million during the quarter, compared to analysts’ expectations of $579.34 million. On average, equities analysts predict that Amedisys, Inc. will post 4.66 earnings per share for the current fiscal year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.